Royal Bank Of Canada Forecasts Strong Price Appreciation for Revvity (NYSE:RVTY) Stock

Revvity (NYSE:RVTY) had its price target hoisted by investment analysts at Royal Bank Of Canada from $135.00 to $172.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price target suggests a potential upside of 6.86% from the stock’s current price.

RVTY has been the subject of several other research reports. Bank of America restated a “neutral” rating on shares of Revvity in a research note on Wednesday. UBS Group assumed coverage on Revvity in a research report on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price objective on the stock. TD Cowen lifted their price objective on Revvity from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. KeyCorp lifted their price objective on Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. Finally, Zacks Research raised Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $127.07.

Revvity Stock Down 1.5%

NYSE RVTY traded down $2.53 during mid-day trading on Wednesday, reaching $160.95. The stock had a trading volume of 1,185,547 shares, compared to its average volume of 1,533,872. Revvity has a 1 year low of $81.22 and a 1 year high of $171.74. The stock has a market cap of $17.96 billion, a PE ratio of 76.48, a price-to-earnings-growth ratio of 2.76 and a beta of 1.08. The company has a fifty day moving average price of $145.89 and a 200 day moving average price of $112.62. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.08. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The business had revenue of $728.90 million for the quarter, compared to analysts’ expectations of $694.73 million. During the same period in the prior year, the firm posted $1.18 EPS. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. On average, research analysts expect that Revvity will post 5.36 earnings per share for the current year.

Insider Buying and Selling at Revvity

In related news, insider Tajinder Vohra sold 7,330 shares of the company’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Maxwell Krakowiak sold 1,631 shares of the company’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the sale, the insider owned 14,781 shares of the company’s stock, valued at approximately $2,136,297.93. This trade represents a 9.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 9,045 shares of company stock valued at $1,281,439 in the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Revvity

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Apollon Wealth Management LLC boosted its holdings in shares of Revvity by 2.7% in the third quarter. Apollon Wealth Management LLC now owns 2,778 shares of the company’s stock worth $425,000 after buying an additional 73 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Revvity by 5.4% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company’s stock valued at $231,000 after buying an additional 106 shares during the period. EverSource Wealth Advisors LLC raised its position in Revvity by 17.0% in the first quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company’s stock worth $66,000 after acquiring an additional 109 shares during the period. Angeles Wealth Management LLC raised its position in Revvity by 2.0% in the second quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company’s stock worth $646,000 after acquiring an additional 112 shares during the period. Finally, Tema ETFs LLC raised its holdings in Revvity by 8.1% in the 2nd quarter. Tema ETFs LLC now owns 1,946 shares of the company’s stock worth $217,000 after purchasing an additional 145 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Key Headlines Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Revvity reported third-quarter adjusted EPS of $1.38, above analyst expectations of about $1.30, and revenue of $728.9 million, up 4.3% year over year and ahead of forecasts. Life Sciences strength and margin expansion helped drive results, and the company raised its 2026 outlook. Article: Q3 earnings beat on Life Sciences strength and 2026 outlook raised
• Positive Sentiment: CFRA upgraded RVTY from “hold” to “buy,” adding a favorable analyst signal following the results.
• Positive Sentiment: Coverage also pointed to AI-related demand and operational execution as contributors to broad-based growth, potentially supporting the company’s outlook. Article: Q3 deep dive on AI demand and operational execution
• Neutral Sentiment: Revvity reaffirmed its dividend, signaling continuity in its shareholder-return policy, though the announcement did not indicate an increase. Article: Revvity reaffirms its dividend
• Negative Sentiment: Some coverage questioned whether RVTY is now too pricey. Valuation concerns could limit further gains after the strong move following the earnings and guidance news. Article: Earnings beat and the case for Revvity stock

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.